There is a lack of research on the effects of bone-modifying agents (BMAs) in patients with metastatic castration-sensitive prostate cancer (mCSPC) who underwent treatment with abiraterone acetate plus prednisone (AAP). A study from Wataru Fukuokaya, MD, and colleagues, published in JAMA Network Open, sought to determine the outcomes associated with BMAs in patients with mCSPC who received AAP. ...
Prostate Cancer
Advertisement
Latest News
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
Dr. Iagaru discusses the safety findings and clinical implications of his research.
Dr. Ulaner highlights 2 new clinical trials for prostate cancer staging and treatment at Hoag: MIRROR and 177Lu-PNT2002.
The data were sourced from a deidentified US-based metastatic prostate cancer clinicogenomic database.
Dr. Gomella tells his journey to becoming a urologist, the importance of multidisciplinary care, and challenges in the field.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Advertisement
Conference Coverage
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
Dr. Canfield shares real-world active surveillance among men with localized PC tested with the genomic prostate score assay.
Advertisement
Advertisement
Latest News
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
The ARON-1 study investigated the efficacy of 1L treatment with TKIs versus IO-based combinations in patients with pRCC.
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
